外周血CYFRA21-1水平与晚期肺癌预后的关系分析

Relation between Prognosis and CYFRA21-1 Level in the Peripheral Blood of Patients with Advanced Lung Cancer

目的探讨晚期肺癌患者治疗前后外周血CYFRA21-1水平与其预后的关系。方法选择晚期肺癌患者148例,采用电化学发光免疫法对所得样本的血清CYFR21-1水平进行检测,将CYFRA21-1水平升高患者纳入高水平组81例,未升高患者纳入低水平组67例。结果化疗前与化疗2个周期时,高水平组患者CYFR21-1水平均显著高于低水平组患者,而经过化疗,高水平组患者的CYFR21-1水平明显下降,差异具有统计学意义(P<0.05);并且经过化疗后,低水平组患者的近期治疗有效率以及1年生存率和生存质量评分均显著高于高水平组患者,差异均具有统计学意义(P<0.05)。结论血清CYFRA21-1的水平可以作为评价晚期非小细胞肺癌患者化疗的疗效指标,也能够对患者的生存期及预后进行评价。

Objective To investigate the relationship between peripheral blood CYFRA21-1 level and prognosis in patients with advanced lung cancer. Methods Serum CYFR21-1 level in 148 advanced lung cancer patients was detected by electrochemiluminescence immunoassay,81 cases with elevated CYFRA21-1 was the high level group,67 cases without increase of CYFRA21-1 was the low level group. Results Before chemotherapy and 2 cycles after chemotherapy,CYFR21-1 level of the high level group was significantly higher than that of the low level group,and after chemotherapy,CYFR21-1 level of the high level group decreased significantly,the difference was statistically significant( P < 0. 05); and after chemotherapy,recent treatment efficiency,1-year survival rate and quality of life scores of the low level group were significantly higher than that of the high level group,the differences were statistically significant( P < 0. 05). Conclusion Serum CYFRA21-1 level could be used as indicators of efficacy evaluation of chemotherapy in patients with advanced non-small cell lung cancer,it can also evaluate the survival and prognosis of the patients.